Skip to main content
. 2020 Sep 19;60(3):423–429. doi: 10.2169/internalmedicine.5317-20

Figure 1.

Figure 1.

A: A 12-lead electrocardiograms during the clinical course in Case 1. B: Cardiac magnetic resonance imaging at diastole (a) and systole (b), dark-blood sequence for non-enhanced T2-weighted imaging (c) and delayed gadolinium-enhanced imaging (d) performed at day 30. C: An immunohistochemical study using endomyocardial biopsy specimens obtained from the septal wall of the right ventricle at day 36 [a, Hematoxylin and Eosin (H&E) staining; b, CD3 (Clone F7.2.38, DakoCytomation); c, PD-1 [anti-PD1 antibody (EPR4877 (2), ab137132, abcam)]; d, CD68 (Clone PG-M1, DakoCytomation); e, PD-L1 (IHC 22C3 pharmDx, DakoCytomation)], and H&E staining (f) in a specimen obtained at day 71. Scale bar, 200 μm. D: Clinical course and changes in the parameters of the left ventricular structure and function, as assessed by a transthoracic echocardiogram. E: Cytokine expressions. F: Creatine kinase (CK), and C-reactive protein (CRP) levels in the clinical course. LVPWTd: left ventricular posterior wall thickness at end-diastole, LVIDd: left ventricular diastolic internal dimension, LVIDs: left ventricular systolic internal dimension, LVEF: left ventricular ejection fraction, PE: pericardial effusion, PSL: prednisolone